Four Ways to Get a Pharma Commercial Question Answered, Compared

Pharma commercial intelligence is the evidence a drug company uses to make commercial decisions: who the competitors are, how many patients can be reached, what payers will accept, and where the opinion leaders sit. There are four ways to get it. Each is the right choice for some questions and the wrong one for others. This comparison sets out what each route gives you and when to use it.

The four routes at a glance

Route 1: a general AI assistant

A general AI assistant is the fastest and cheapest route, and most commercial teams already use one. It is good for orientation: the shape of a market, the names of the approved drugs, the vocabulary of an unfamiliar disease.

Its weakness is that a confident answer can rest on an old or mismatched source. On 6 October 2026 we asked three assistants the same question: how many orphan drug approvals has the FDA granted since 1983? One answered "more than 780", one "over 1,100" and one "well over 1,000". The FDA's own register, counted on our orphan drug approvals page, shows 1,437 to July 2026. Each assistant cited a source. The sources dated from different years and counted different things: first approvals, distinct drugs, or all approved uses. A reader with only the answer cannot tell which.

Use a general assistant to get oriented. Do not put its figure in front of a payer or a leadership team without opening the source.

Route 2: a syndicated report

A syndicated report is written once and sold to many buyers. DelveInsight publishes disease-level reports that combine epidemiology, marketed drugs, pipeline and a market forecast. GlobalData sells pharmaceutical intelligence through a subscription platform and reports.

The strength is breadth. For a large, well-studied market a syndicated report gives a full background document on the day you buy it. The limit is that it was not written for your asset, your market or your question. A report on a disease worldwide will say little about one country's reimbursement route or one hospital network's referral pattern, and it cannot be asked a follow-up.

Route 3: a consulting firm

A consulting firm assigns a team to your question. The large firms now pair that team with their own AI platform: ZS describes ZAIDYN as a commercial analytics platform, powered by AI, that connects field planning, customer engagement, insights and incentives, and IQVIA offers Commercial Agentic AI on top of the data it licenses.

This is the right route when the decision needs things only a staffed engagement provides: interviews with physicians and payers, proprietary prescription data, or a system your organisation will run every day. It is slow and expensive for a single, bounded question, and a finding that arrives after the decision has been made changes nothing.

Route 4: an AI-native pharma engine

An AI-native engine is built for one job: taking a specific commercial question and returning a finished, sourced answer quickly. AXLRx, built by MoatRx, is one. A team brings a question for a drug, a market and a buyer. The engine researches it across live sources, removes any figure it cannot trace to the source it cites, and returns a consulting deliverable. Scope is confirmed in 24 hours and delivery takes 72. The work covers four modules: KOL mapping, competitive intelligence, clinical trial analytics and patient flow.

This route has limits too. AXLRx holds no proprietary prescription data and runs no field systems. Its published work is desk research, so interviews happen only when primary research is commissioned separately. Other AI-native providers serve pharma, and any of them can be judged on the same four tests below. The methodology page sets out our sourcing standard and its limits.

Four tests to apply to any route

• Fit. Was the answer written for your asset, your market and your question, or for a general reader?
• Traceability. Can each figure be followed to a named source, and what happens to a figure that cannot?
• Time. Will the answer arrive before the decision is made?
• Operating burden. Do you receive a finished answer, or a tool your team has to learn and run?

These tests are covered in more depth in how to buy a competitive-intelligence brief that changes a decision.

How to choose

• You are new to the disease and need the basics today. Start with a general AI assistant, and check what it tells you.
• You need a broad background document on a large market. Buy a syndicated report.
• The decision needs interviews, proprietary data or a system you will run. Hire a consulting firm.
• You have one commercial question and a decision due this month. Commission an AI-native engine.

The routes are often used together. A team can read a syndicated report for background, use an assistant to explore, and still commission a sourced answer for the one question the decision turns on.

How this comparison was built

Each description of another firm is that firm's own account of its product, taken from its website on 6 October 2026 and linked above. No price or performance claim from any firm is repeated, because none could be checked independently. The AI assistant test was run by us on the date stated, with each assistant asked the question once. AXLRx is our own product, so read that section as the seller's view. A longer guide is in pharma commercial consulting: a buyer's guide.